<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Observational studies report that higher intake of dietary fibre (a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> mix including non-<z:chebi fb="99" ids="28017">starch</z:chebi> <z:chebi fb="5" ids="18154">polysaccharides</z:chebi> and resistant starches) is associated with reduced risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, but no randomised trials with prevention of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> as a primary endpoint have been done </plain></SENT>
<SENT sid="1" pm="."><plain>We assessed the effect of resistant <z:chebi fb="99" ids="28017">starch</z:chebi> on the incidence of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: In the CAPP2 study, individuals with <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> were randomly assigned in a two-by-two factorial design to receive 600 mg aspirin or aspirin placebo or 30 g resistant <z:chebi fb="99" ids="28017">starch</z:chebi> or <z:chebi fb="99" ids="28017">starch</z:chebi> placebo, for up to 4 years </plain></SENT>
<SENT sid="3" pm="."><plain>Randomisation was done with a block size of 16 </plain></SENT>
<SENT sid="4" pm="."><plain>Post-intervention, patients entered into double-blind follow-up; participants and investigators were masked to treatment allocation </plain></SENT>
<SENT sid="5" pm="."><plain>The primary endpoint for this analysis was development of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> in participants randomly assigned to resistant <z:chebi fb="99" ids="28017">starch</z:chebi> or resistant-<z:chebi fb="99" ids="28017">starch</z:chebi> placebo with both intention-to-treat and per-protocol analyses </plain></SENT>
<SENT sid="6" pm="."><plain>This study is registered, ISRCTN 59521990 </plain></SENT>
<SENT sid="7" pm="."><plain>FINDINGS: 463 patients were randomly assigned to receive resistant <z:chebi fb="99" ids="28017">starch</z:chebi> and 455 to receive resistant-<z:chebi fb="99" ids="28017">starch</z:chebi> placebo </plain></SENT>
<SENT sid="8" pm="."><plain>At a median follow-up 52·7 months (IQR 28·9-78·4), 53 participants developed 61 primary <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> (27 of 463 participants randomly assigned to resistant <z:chebi fb="99" ids="28017">starch</z:chebi>, 26 of 455 participants assigned to resistant-<z:chebi fb="99" ids="28017">starch</z:chebi> placebo) </plain></SENT>
<SENT sid="9" pm="."><plain>Intention-to-treat analysis of time to first <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> showed a hazard ratio (HR) of 1·40 (95% CI 0·78-2·56; p=0·26) and Poisson regression accounting for multiple primary events gave an incidence rate ratio (IRR) of 1·15 (95% CI 0·66-2·00; p=0·61) </plain></SENT>
<SENT sid="10" pm="."><plain>For those completing 2 years of intervention, per-protocol analysis yielded a HR of 1·09 (0·55-2·19, p=0·80) and an IRR of 0·98 (0·51-1·88, p=0·95) </plain></SENT>
<SENT sid="11" pm="."><plain>No information on adverse events was gathered during post-intervention follow-up </plain></SENT>
<SENT sid="12" pm="."><plain>INTERPRETATION: Resistant <z:chebi fb="99" ids="28017">starch</z:chebi> had no detectable effect on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> development in carriers of hereditary <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>Dietary supplementation with resistant <z:chebi fb="99" ids="28017">starch</z:chebi> does not emulate the apparently protective effect of diets rich in dietary fibre against <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>FUNDING: European Union, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Research UK, Bayer Corporation, National <z:chebi fb="99" ids="28017">Starch</z:chebi> and Chemical Co, UK Medical Research Council, Newcastle Hospitals Trustees, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Council of Victoria Australia, THRIPP South Africa, The Finnish <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Foundation, SIAK Switzerland, and Bayer Pharma </plain></SENT>
</text></document>